Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NC › Burlington › NPI 1902809940
Lab

Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings was paid $264.26M by Medicaid between Jan 2018 and Dec 2024, across 547 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 22% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA HOLDINGS
BURLINGTON, NC 27215
33aNPI1902809940assigned 05/23/2005
33bProvider typeClinical Medical Laboratory
28Total paid$264.26M
24GClaims15,254,290
24DCodes billed547
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#3 of 128
Median peer was paid$268K
This provider vs. median986×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$5.0M$10M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20181,476,739$22.14M
20191,767,106$27.02M
20202,169,681$53.06M
20213,140,695$59.13M
20222,796,606$47.36M
20232,440,799$34.77M
2024incomplete1,462,664$20.76M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 22% 978,195 887,663 $58.83M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 8.6% 588,417 358,351 $22.80M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 5.2% 22,938 22,532 $13.81M
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 4.9% 84,309 79,431 $13.04M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 3.3% 451,863 427,780 $8.83M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 3.3% 453,264 428,808 $8.81M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 2.7% 507,515 465,312 $7.05M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 2.6% 344,860 331,426 $6.92M
86769 2.1% 155,470 154,156 $5.55M
80053 Comprehensive metabolic panel 2.1% 809,798 772,901 $5.46M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.9% 116,240 64,151 $4.99M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.7% 237,603 222,730 $4.52M
535 more codes
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 1.7% 113,825 $4.39M
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 1.7% 61,126 $4.37M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.5% 13,917 $4.08M
80061 Lipid panel 1.5% 675,350 $3.91M
84443 Thyroid stimulating hormone (TSH) 1.4% 536,895 $3.77M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.3% 243,192 $3.46M
81229 1.3% 3,782 $3.35M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.1% 87,768 $3.01M
83036 Hemoglobin; glycosylated (A1C) <1% 403,754 $2.61M
86480 <1% 78,852 $2.52M
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 803,277 $2.32M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 108,373 $2.21M
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 27,105 $2.17M
80050 General health panel <1% 104,568 $2.11M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types <1% 79,478 $1.87M
86003 <1% 27,008 $1.69M
82607 <1% 182,975 $1.61M
84439 <1% 258,462 $1.55M
87086 Culture, bacterial; quantitative colony count, urine <1% 235,660 $1.35M
86803 <1% 163,408 $1.28M
87536 <1% 20,200 $1.20M
82746 <1% 132,760 $1.15M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 18,126 $1.09M
84403 <1% 53,922 $1000K
82728 <1% 106,174 $975K
83655 <1% 110,647 $973K
84153 <1% 75,040 $953K
80081 <1% 17,956 $921K
80074 <1% 32,989 $891K
87340 <1% 128,759 $887K
87902 <1% 4,878 $874K
81162 <1% 526 $825K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 13,246 $798K
87522 Neg quan hep c or qual rna <1% 24,979 $742K
84702 <1% 72,338 $638K
82670 <1% 32,907 $638K
84402 <1% 34,491 $615K
86235 <1% 18,797 $574K
81001 <1% 254,264 $564K
83013 <1% 11,903 $557K
86780 <1% 61,195 $557K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 2,134 $555K
83001 <1% 41,988 $552K
87081 <1% 128,071 $546K
87507 <1% 1,905 $523K
84146 <1% 37,298 $521K
83002 <1% 40,224 $514K
86618 <1% 28,193 $500K
86592 <1% 202,749 $497K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 16,139 $477K
83540 <1% 127,842 $438K
83550 <1% 105,267 $428K
83970 <1% 15,701 $419K
86762 <1% 42,319 $402K
82043 <1% 117,588 $400K
84144 <1% 28,646 $399K
86706 <1% 65,101 $396K
87088 <1% 67,821 $391K
87186 <1% 68,291 $391K
83516 <1% 24,539 $372K
86376 <1% 36,879 $371K
87070 <1% 61,826 $368K
80048 Basic metabolic panel (calcium, ionized) <1% 72,706 $366K
82570 <1% 107,015 $364K
86360 <1% 11,819 $364K
86696 <1% 28,384 $360K
82784 <1% 37,084 $356K
85027 <1% 120,473 $356K
84436 <1% 90,527 $343K
86765 <1% 38,184 $335K
87077 <1% 55,203 $317K
87150 <1% 24,423 $313K
86617 <1% 13,629 $283K
86038 <1% 51,661 $265K
82627 <1% 17,335 $263K
86787 <1% 39,710 $253K
82105 <1% 33,233 $253K
86704 <1% 37,985 $250K
87529 <1% 9,286 $237K
88142 <1% 15,367 $237K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 16,363 $236K
87517 <1% 8,599 $228K
86140 <1% 75,521 $228K
81329 <1% 5,527 $227K
86665 <1% 10,412 $227K
86800 <1% 24,477 $226K
84480 <1% 49,183 $219K
86708 <1% 31,677 $218K
84481 <1% 30,101 $216K
86317 <1% 31,498 $207K
86735 <1% 36,626 $203K
83735 <1% 56,048 $202K
84154 <1% 15,468 $197K
81596 <1% 5,181 $193K
84550 <1% 67,541 $193K
86695 <1% 25,595 $192K
87660 <1% 19,431 $190K
81003 <1% 131,969 $188K
88141 <1% 14,126 $186K
82248 <1% 52,468 $167K
83880 <1% 7,302 $165K
87563 <1% 11,378 $164K
87481 <1% 5,372 $159K
83498 <1% 8,164 $157K
87480 <1% 15,717 $156K
87510 <1% 15,714 $156K
83525 <1% 21,140 $155K
83021 <1% 12,361 $154K
80076 <1% 30,988 $153K
81243 <1% 5,516 $149K
82785 <1% 14,025 $146K
84479 <1% 50,725 $144K
86364 <1% 16,154 $142K
86008 <1% 6,800 $141K
81374 <1% 5,004 $139K
83921 <1% 10,083 $138K
85652 <1% 87,915 $138K
86160 <1% 10,616 $136K
85610 <1% 51,269 $135K
82652 <1% 5,620 $133K
80321 <1% 3,677 $133K
82533 <1% 11,130 $129K
86200 <1% 15,127 $125K
83020 <1% 14,044 $125K
86850 <1% 30,216 $123K
82172 <1% 11,958 $123K
82677 <1% 8,103 $122K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 1,692 $122K
86431 <1% 32,496 $122K
82274 <1% 27,295 $122K
83520 <1% 12,146 $119K
82950 <1% 32,674 $118K
82977 <1% 35,924 $115K
84681 <1% 6,962 $104K
86361 <1% 6,035 $102K
86225 <1% 18,247 $96K
84460 <1% 28,993 $93K
84445 <1% 5,142 $92K
84425 <1% 8,665 $91K
84450 <1% 39,070 $89K
82465 <1% 29,274 $88K
83690 <1% 20,297 $88K
84075 <1% 28,184 $87K
82024 <1% 3,236 $87K
87625 <1% 4,338 $86K
82672 <1% 5,900 $85K
86147 <1% 5,704 $85K
86709 <1% 12,234 $85K
86336 <1% 9,689 $85K
83993 <1% 9,019 $85K
80348 <1% 26,153 $84K
84100 <1% 33,494 $84K
82550 <1% 23,756 $84K
84270 <1% 6,259 $83K
80055 <1% 3,222 $82K
84305 <1% 6,027 $81K
82565 <1% 38,195 $81K
87338 <1% 12,168 $79K
82310 <1% 25,339 $78K
87427 <1% 9,020 $78K
86258 <1% 7,616 $76K
88230 <1% 1,205 $76K
85730 <1% 19,950 $75K
86664 <1% 7,079 $74K
82947 <1% 35,201 $73K
87177 <1% 11,182 $72K
87521 Neg quan hep c or qual rna <1% 2,472 $71K
87900 <1% 661 $67K
83704 <1% 3,156 $67K
87209 <1% 11,142 $67K
86231 <1% 10,789 $66K
86334 <1% 4,251 $65K
86141 <1% 8,946 $65K
82626 <1% 4,099 $64K
87075 <1% 9,529 $64K
83883 <1% 9,100 $64K
86901 <1% 30,004 $64K
80164 <1% 8,432 $64K
87255 <1% 4,705 $64K
82150 <1% 16,419 $63K
86256 <1% 3,610 $61K
86255 <1% 9,921 $61K
83615 <1% 22,296 $59K
84478 <1% 17,221 $58K
83010 <1% 6,636 $58K
88262 <1% 529 $58K
85660 <1% 16,200 $57K
88185 <1% 162 $57K
86900 <1% 26,543 $56K
86677 <1% 5,749 $55K
82247 <1% 33,970 $54K
84520 <1% 34,212 $54K
86747 <1% 2,976 $53K
86666 <1% 2,896 $53K
84156 <1% 20,386 $53K
84165 <1% 7,336 $52K
80354 <1% 10,674 $52K
86146 <1% 3,087 $51K
82951 <1% 7,010 $51K
82378 <1% 3,707 $51K
84207 <1% 2,665 $50K
87535 <1% 3,169 $49K
86705 <1% 11,427 $47K
80358 <1% 15,112 $47K
87101 <1% 8,370 $46K
88342 <1% 966 $46K
87901 <1% 261 $46K
87045 <1% 8,995 $46K
87350 <1% 7,335 $45K
86359 <1% 2,761 $45K
87650 <1% 8,216 $44K
82040 <1% 30,061 $44K
36415 Collection of venous blood by venipuncture <1% 54,107 $43K
80177 <1% 5,417 $41K
86707 <1% 6,396 $40K
80346 <1% 10,266 $39K
80069 <1% 7,207 $39K
80349 <1% 15,334 $39K
88112 <1% 1,994 $38K
84466 <1% 4,935 $38K
83090 <1% 3,376 $38K
80197 <1% 5,346 $38K
82157 <1% 1,911 $37K
80361 <1% 10,200 $37K
84155 <1% 28,414 $36K
86757 <1% 1,440 $36K
85045 <1% 14,018 $35K
84630 <1% 5,910 $35K
80365 <1% 9,669 $35K
87493 <1% 1,721 $35K
80353 <1% 9,739 $34K
86644 <1% 3,542 $34K
82525 <1% 3,903 $34K
80051 <1% 7,967 $33K
83721 <1% 9,749 $33K
88360 <1% 240 $32K
86671 <1% 3,356 $32K
86753 <1% 2,891 $32K
80178 <1% 7,128 $32K
88312 <1% 592 $31K
87329 <1% 3,586 $30K
86060 <1% 8,278 $30K
82397 <1% 4,756 $30K
84590 <1% 3,710 $29K
84132 <1% 16,348 $29K
84295 <1% 22,112 $29K
86663 <1% 2,929 $28K
86304 <1% 1,949 $28K
86037 <1% 2,399 $28K
80359 <1% 7,508 $28K
81377 <1% 426 $28K
80372 <1% 5,504 $28K
84703 <1% 9,459 $27K
87581 <1% 1,019 $27K
87486 <1% 1,019 $27K
82103 <1% 3,307 $27K
80373 <1% 5,709 $27K
86381 <1% 2,311 $27K
80360 <1% 3,883 $26K
82435 <1% 21,842 $26K
81401 <1% 439 $26K
86738 <1% 1,633 $26K
85018 <1% 16,231 $26K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,344 $26K
82390 <1% 4,555 $26K
86593 <1% 8,810 $26K
85613 <1% 3,808 $26K
87799 <1% 967 $25K
82088 <1% 918 $25K
84410 <1% 737 $25K
81201 <1% 49 $25K
84163 <1% 2,535 $24K
86694 <1% 3,369 $23K
86777 <1% 2,464 $23K
87324 <1% 3,725 $23K
83521 <1% 1,932 $22K
86645 <1% 3,937 $22K
82653 <1% 2,187 $22K
86356 <1% 494 $22K
85014 <1% 12,432 $21K
87184 <1% 4,609 $21K
87254 <1% 777 $21K
87046 <1% 9,027 $21K
86702 <1% 2,770 $20K
84378 <1% 2,592 $20K
81479 Unlisted molecular pathology procedure <1% 227 $20K
80337 <1% 4,203 $20K
87506 <1% 156 $20K
84446 <1% 2,045 $19K
82668 <1% 1,726 $19K
80370 <1% 4,196 $19K
81241 <1% 784 $19K
82164 <1% 2,154 $19K
87593 <1% 455 $18K
80368 <1% 4,142 $18K
87497 <1% 1,009 $18K
84432 <1% 3,513 $18K
82747 <1% 2,175 $18K
80366 <1% 5,733 $18K
88304 <1% 669 $17K
80334 <1% 4,121 $17K
80338 <1% 4,036 $17K
80362 <1% 6,755 $17K
80364 <1% 3,986 $17K
83992 <1% 4,819 $16K
85379 <1% 2,426 $16K
80371 <1% 2,803 $16K
80377 <1% 2,597 $16K
86335 <1% 802 $15K
87206 <1% 4,346 $15K
83695 <1% 2,015 $15K
80324 <1% 6,188 $15K
80344 <1% 2,759 $15K
80326 <1% 2,579 $15K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 1,525 $14K
80341 <1% 3,439 $14K
86015 <1% 2,953 $14K
80347 <1% 5,403 $14K
86701 <1% 2,583 $14K
80367 <1% 2,680 $14K
80357 <1% 3,636 $14K
86341 <1% 975 $14K
82330 <1% 3,143 $13K
81206 <1% 519 $13K
81270 <1% 446 $13K
86162 <1% 1,160 $13K
86355 <1% 860 $13K
86778 <1% 1,413 $13K
82952 <1% 5,802 $13K
86215 <1% 3,667 $13K
86870 <1% 562 $12K
80331 <1% 2,545 $12K
80355 <1% 4,983 $12K
86300 <1% 730 $12K
81025 <1% 5,440 $11K
84134 <1% 2,124 $11K
86301 <1% 826 $11K
82679 <1% 648 $11K
83014 <1% 2,260 $11K
84244 <1% 806 $11K
80159 <1% 1,296 $10K
84166 <1% 1,352 $10K
85732 <1% 2,426 $10K
87906 <1% 115 $10K
80175 <1% 1,294 $10K
85060 <1% 1,010 $10K
87538 <1% 364 $10K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 2,570 $10K
87631 <1% 168 $10K
82610 <1% 1,384 $10K
88313 <1% 193 $10K
83003 <1% 627 $10K
82166 <1% 638 $10K
82374 <1% 8,446 $10K
82787 <1% 723 $9K
82239 <1% 725 $9K
87109 <1% 1,621 $9K
99199 Unlisted special service, procedure or report <1% 2,487 $9K
84252 <1% 688 $8K
86308 <1% 2,568 $8K
83718 <1% 1,360 $8K
81422 <1% 134 $8K
81257 <1% 457 $8K
83835 <1% 650 $7K
82085 <1% 1,278 $7K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 195 $7K
87106 <1% 1,143 $7K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 1,357 $7K
83631 <1% 967 $7K
81207 <1% 456 $7K
82140 <1% 731 $7K
87076 <1% 1,274 $7K
85048 <1% 3,163 $7K
82985 <1% 942 $6K
85670 <1% 1,801 $6K
80299 <1% 740 $6K
85240 <1% 877 $6K
85041 <1% 2,432 $6K
85306 <1% 470 $6K
87476 <1% 436 $6K
84482 <1% 1,586 $6K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 223 $6K
85246 <1% 779 $6K
88184 <1% 164 $6K
82180 <1% 846 $5K
80185 <1% 657 $5K
85384 <1% 1,064 $5K
82955 <1% 745 $5K
83825 <1% 438 $5K
86357 <1% 316 $5K
85598 <1% 601 $5K
81490 <1% 723 $5K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 507 $5K
86036 <1% 833 $5K
85004 <1% 849 $4K
85007 <1% 2,586 $4K
89055 <1% 1,798 $4K
81383 <1% 137 $4K
87210 <1% 1,524 $4K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 28 $4K
85245 <1% 575 $4K
80183 <1% 489 $4K
81405 <1% 185 $4K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 893 $4K
87205 <1% 1,706 $4K
83527 <1% 473 $4K
82705 <1% 1,164 $4K
81404 <1% 161 $4K
81240 <1% 245 $3K
86340 <1% 431 $3K
81256 <1% 359 $3K
84080 <1% 475 $3K
81292 <1% 53 $3K
86880 <1% 1,000 $3K
81406 <1% 179 $3K
80156 <1% 398 $3K
85705 <1% 599 $3K
84255 <1% 196 $3K
85049 <1% 810 $3K
81408 <1% 85 $3K
84484 <1% 426 $3K
86005 <1% 1,023 $3K
82553 <1% 503 $3K
88189 <1% 40 $3K
80323 <1% 1,251 $3K
86148 <1% 172 $2K
86337 <1% 285 $2K
81407 <1% 123 $2K
82175 <1% 176 $2K
80320 <1% 858 $2K
82552 <1% 211 $2K
81403 <1% 125 $2K
81251 <1% 225 $2K
85305 <1% 243 $2K
87807 <1% 182 $2K
84202 <1% 311 $2K
81432 <1% 12 $2K
83789 <1% 152 $2K
87252 <1% 88 $2K
G0475 Hiv antigen/antibody, combination assay, screening <1% 183 $2K
84152 <1% 113 $1K
87468 <1% 105 $1K
82232 <1% 183 $1K
84597 <1% 142 $1K
81290 <1% 224 $1K
81209 <1% 224 $1K
87420 <1% 212 $1K
85300 <1% 216 $1K
81015 <1% 873 $1K
81433 <1% 12 $1K
82340 <1% 269 $1K
84591 <1% 419 $1K
86658 <1% 57 $902.71
85302 <1% 109 $899.73
85303 <1% 101 $882.58
87634 <1% 17 $842.40
81255 <1% 244 $816.58
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 101 $804.23
87328 <1% 86 $803.01
81002 <1% 563 $797.41
83519 <1% 76 $766.37
80165 <1% 92 $746.74
82384 <1% 56 $731.20
80202 <1% 113 $729.20
84442 <1% 120 $707.01
80184 <1% 113 $691.53
87275 <1% 73 $670.24
87276 <1% 72 $660.80
81402 <1% 12 $644.64
81244 <1% 59 $636.84
87040 <1% 107 $632.07
99001 <1% 3,428 $615.26
82530 <1% 40 $510.05
82656 <1% 67 $460.79
81291 <1% 254 $412.96
81298 <1% 51 $411.53
81295 <1% 52 $405.56
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 80 $350.47
81294 <1% 45 $345.00
81297 <1% 43 $345.00
81323 <1% 93 $345.00
81242 <1% 224 $341.03
81219 <1% 89 $313.66
80363 <1% 22 $307.34
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 71 $285.26
85597 <1% 39 $281.56
86682 <1% 41 $276.83
81200 <1% 224 $263.40
81351 <1% 81 $260.60
81330 <1% 224 $253.44
87999 <1% 30 $249.50
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 27 $238.70
81361 <1% 223 $236.19
80375 <1% 595 $232.42
81321 <1% 101 $213.06
81260 <1% 224 $211.25
87280 <1% 19 $199.56
81317 <1% 50 $194.95
82300 <1% 15 $189.99
85301 <1% 26 $182.17
87015 <1% 87 $160.47
87260 <1% 12 $153.89
82657 <1% 28 $149.40
0099U <1% 457 $145.80
83935 <1% 36 $142.92
86615 <1% 15 $141.17
80356 <1% 486 $131.67
81338 <1% 78 $117.44
82139 <1% 13 $104.17
80162 <1% 16 $83.45
87230 <1% 12 $76.32
81279 <1% 53 $72.34
86226 <1% 15 $72.00
86635 <1% 12 $60.84
80305 <1% 432 $53.28
80145 <1% 135 $49.29
36416 <1% 932 $45.65
80345 <1% 196 $37.18
80352 <1% 19 $33.50
80325 <1% 89 $30.42
82642 <1% 197 $28.62
85046 <1% 173 $17.40
80376 <1% 154 $16.11
81307 <1% 79 $14.01
0097U 0% 121 $0.00
87653 0% 39 $0.00
81300 0% 42 $0.00
81381 0% 16 $0.00
81319 0% 42 $0.00
80332 0% 115 $0.00
80369 0% 22 $0.00
0064U 0% 408 $0.00
82962 0% 181 $0.00
81203 0% 30 $0.00
80374 0% 106 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VICE PRESIDENT)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaSeattle, WA$186.69M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.